Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Date Insider Type Main position Quantity % Market Cap.
6/22/22 Free 111,193 0.2314%
1/19/21 Sell 1 0.0000%
1/19/21 Sell 2,000 0.0179%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
+0.12%+3.83%+43.38%-1.11% 79.58B
-3.73%+3.89%-1.33%+25.77% 52.73B
-1.95%-3.23%+18.58%+170.42% 49.77B
-0.90%+3.68%-49.09%-47.82% 46.77B
+2.44%+1.08%+62.00%-23.68% 30.13B
-0.25%+0.81%+47.98%+83.18% 24.54B
+5.12%+13.18%+148.13%-37.26% 24.18B
+0.68%+5.66%+1.16%+196.60% 21.2B
+0.17%+2.26%+70.79%+169.84% 16.36B
Average -7.34%+4.20%+37.96%+59.55% 38.36B
Weighted average by Cap. -0.34%+3.58%+28.45%+43.12%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock